title: Effects of jnk inhibitor on inflammation and fibrosis in the ovary tissue of a rat model of polycystic ovary syndrome.
abstract: OBJECTIVE
  In our study, we aimed to investigate the effects of Jun N-terminal kinase inhibitor (SP600125) on fibrosis and inflammation in rats with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  50 Wistar-albino rats were divided into five groups (n=10 each): control group, sham group, PCOS group, SP600125+ PCOS group and SP600125 group. In the estradiol valerate (EV)-treated group in which PCOS was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil and the rats were sacrificed on day 60. The estradiol valerate (EV)-treated + SP600125-treated group was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil. As of day 60, the treatment group was additionally given 15 mg/kg i.p. of SP600125 once daily for 4 consecutive days and the rats were sacrificed on day 65. Histopathological findings (ovarian morphology, edema, inflammatory cell infiltration, vascular congestion and hyperemia) and collagen type IV immunoexpression were assessed.
  
  
  RESULTS
  The SP600125+ PCOS group showed a significant level of improvement in ovarian follicle morphology, edema, inflammatory infiltrate, vascular congestion and hyperemia as compared with the PCOS group. Furthermore, collagen type IV immunoexpression showed a significant reduction in staining intensity on the theca cell layer and ovary stroma as compared to the PCOS group.
  
  
  CONCLUSIONS
  This study demonstrates the therapeutic effect of SP600125 in the prevention of PCOS in an experimental model.
authors.affiliation: Department of Pathology, Yuzuncu Yil University Faculty of Medicine Van, Turkey.
authors.forename: Gulay
authors.initials: G
authors.lastname: Bulut
authors.affiliation: Department of Obstetrics and Gynecology, Ankara Education and Research Hospital Ankara, Turkey.
authors.forename: Zehra
authors.initials: Z
authors.lastname: Kurdoglu
authors.affiliation: Department of Histology and Embryology, Faculty of Medicine, Namık Kemal University Tekirdag-Turkey.
authors.forename: Yeliz Bozdemir
authors.initials: YB
authors.lastname: Dönmez
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Gazi University Ankara, Turkey.
authors.forename: Mertihan
authors.initials: M
authors.lastname: Kurdoglu
authors.affiliation: Department of Pathology, Yuzuncu Yil University Faculty of Medicine Van, Turkey.
authors.forename: Remzi
authors.initials: R
authors.lastname: Erten
mesh_terms: D000818:Animals; D000873:Anthracenes / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D005355:Fibrosis / Q000473:pathology; D007150:Immunohistochemistry; D007249:Inflammation / Q000473:pathology*; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors; D011085:Polycystic Ovary Syndrome / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000873:Anthracenes; D047428:Protein Kinase Inhibitors; C432165:pyrazolanthrone; D048670:MAP Kinase Kinase 4
keywords: Fibrosis; Jun N-terminal kinase inhibitor; inflammation; polycystic ovary syndrome